Page 302 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 302
Fatty Liver Disease: Clinical (Cont.)
TOP 10% ULTRA-HIGH-FIELD MR-SPECTROSCOPY IN NAFLD
YI P1045 AS NON-INVASIVE IN-VIVO TOOL FOR MONITORING
CHANGES IN FAT AND ENERGY METABOLISM WITH
POTENTIAL IDENTIFICATION OF NASH AND ADVANCED
FIBROSIS BY SATURATION TRANSFER TECHNIQUE
Stefan Traussnigg*, Christian Kienbacher, Martin Gajdošík,
Ladislav Valkovič, Harald Hofer, Peter Ferenci, Friedrich Wrba,
Siegfried Trattnig, Martin Krššák, Michael Trauner, Austria
TOP 10% A ONE YEAR RETROSPECTIVE REVIEW OF NEW PATIENT
YI P1046 ATTENDANCES AT A TERTIARY HEPATOLOGY CENTRE
HIGHLIGHTING THE INCREASING CHALLENGE OF NAFLD
AND THE NEED TO DEVELOP CLINICAL PATHWAYS
Ankur Srivastava*, Ruth Gailer, Sudeep Tanwar, Paul Trembling,
Alex Warner, Sarah Morgan, Karen Sennett, Douglas Thorburn,
Emmanouil Tsochatzis, William Rosenberg, The United Kingdom
TOP 10% CONTROLLED ATTENUATION PARAMETER (CAP):
YI P1047 COMBINATION OF M AND XL PROBE IMPROVES
FEASIBILITY AND ACCURACY FOR DISCRIMINATING
ePOSTERS ADVANCED GRADES OF STEATOSIS
Thomas Karlas*, Nikita Garnov, Franziska Lindner, Harald Busse,
Nicolas Linder, Alexander Schaudinn, Bettina Relke, Rima Chakaroun,
Michael Tröltzsch, Volker Keim, Johannes Wiegand, Germany
YI P1048 EFFECTS OF PROSTEATOGENIC TM6SF2 AND NCAN/SUGP1
VARIANTS ON HEPATIC STEATOSIS AND NON-INVASIVE
MARKERS OF LIVER INJURY IN PATIENTS WITH CHRONIC
LIVER DISEASES
Anita Arslanow*, Caroline S. Stokes, Frank Grünhage, Frank Lammert,
Marcin Krawczyk, Germany
YI P1049 LYSOSOMAL ACIDE LIPASE ACTIVITY IN PATIENTS WITH
NON-ALCOHOLIC FATTY LIVER DISEASE
Daniele Pastori*, Francesco Baratta, Lica Polimeni, Fiorella Piemonte,
Giulia Tozzi, Serena Di Santo, Daniela Salzano, Arianna Pani,
Francesco Violi, Maria Del Ben, Francesco Angelico, Italy
302 The International Liver Congress™ 2015 • ILC Programme
TOP 10% ULTRA-HIGH-FIELD MR-SPECTROSCOPY IN NAFLD
YI P1045 AS NON-INVASIVE IN-VIVO TOOL FOR MONITORING
CHANGES IN FAT AND ENERGY METABOLISM WITH
POTENTIAL IDENTIFICATION OF NASH AND ADVANCED
FIBROSIS BY SATURATION TRANSFER TECHNIQUE
Stefan Traussnigg*, Christian Kienbacher, Martin Gajdošík,
Ladislav Valkovič, Harald Hofer, Peter Ferenci, Friedrich Wrba,
Siegfried Trattnig, Martin Krššák, Michael Trauner, Austria
TOP 10% A ONE YEAR RETROSPECTIVE REVIEW OF NEW PATIENT
YI P1046 ATTENDANCES AT A TERTIARY HEPATOLOGY CENTRE
HIGHLIGHTING THE INCREASING CHALLENGE OF NAFLD
AND THE NEED TO DEVELOP CLINICAL PATHWAYS
Ankur Srivastava*, Ruth Gailer, Sudeep Tanwar, Paul Trembling,
Alex Warner, Sarah Morgan, Karen Sennett, Douglas Thorburn,
Emmanouil Tsochatzis, William Rosenberg, The United Kingdom
TOP 10% CONTROLLED ATTENUATION PARAMETER (CAP):
YI P1047 COMBINATION OF M AND XL PROBE IMPROVES
FEASIBILITY AND ACCURACY FOR DISCRIMINATING
ePOSTERS ADVANCED GRADES OF STEATOSIS
Thomas Karlas*, Nikita Garnov, Franziska Lindner, Harald Busse,
Nicolas Linder, Alexander Schaudinn, Bettina Relke, Rima Chakaroun,
Michael Tröltzsch, Volker Keim, Johannes Wiegand, Germany
YI P1048 EFFECTS OF PROSTEATOGENIC TM6SF2 AND NCAN/SUGP1
VARIANTS ON HEPATIC STEATOSIS AND NON-INVASIVE
MARKERS OF LIVER INJURY IN PATIENTS WITH CHRONIC
LIVER DISEASES
Anita Arslanow*, Caroline S. Stokes, Frank Grünhage, Frank Lammert,
Marcin Krawczyk, Germany
YI P1049 LYSOSOMAL ACIDE LIPASE ACTIVITY IN PATIENTS WITH
NON-ALCOHOLIC FATTY LIVER DISEASE
Daniele Pastori*, Francesco Baratta, Lica Polimeni, Fiorella Piemonte,
Giulia Tozzi, Serena Di Santo, Daniela Salzano, Arianna Pani,
Francesco Violi, Maria Del Ben, Francesco Angelico, Italy
302 The International Liver Congress™ 2015 • ILC Programme
